Melanoma
From the Journals
No benefit to adding limited radiation in advanced cancer
Median overall survival was not significantly better with radiotherapy, compared with the control group, nor was the objective response rate.
Latest News
Imaging techniques will revolutionize cancer detection, expert predicts
Jennifer Barton, PhD, and her colleagues are developing an OCT/fluorescence imaging falloposcope that is 0.8 mm in diameter, flexible, and...
Conference Coverage
Multiprong strategy makes clinical trials less White
Only a small percentage of eligible patients participate in clinical trials in the first place, and very few come from racial and ethnic minority...
Conference Coverage
CBSM phone app eases anxiety, depression in cancer patients
Few patients with cancer have access to psycho-oncologic support.
Conference Coverage
Huge underuse of germline testing for cancer patients
Information from germline genetic testing could affect a patient’s cancer care.
Conference Coverage
DEI training gives oncology fellows more confidence
Only 2%-3% of practicing oncologists are Black or Hispanic/Latino, says Yale Cancer Center doctor.
Feature
Drugmakers are abandoning cheap generics, and now U.S. cancer patients can’t get meds
On Nov. 22, three FDA inspectors arrived at the sprawling Intas Pharmaceuticals plant south of Ahmedabad, India, and found hundreds of trash bags...
Latest News
Experts share their sun protection tips for children
Most sunscreens are not approved for use in children under the age of 6 months because testing has not been done in this age group, Dr. Adelaide A...
Conference Coverage
ACS officer provides ASCO highlights: Targeting hidden cancer, AI in oncology
A pair of new studies show that drugs can reduce cancer risk when cells are elusive.
Latest News
Antibiotic prophylaxis may lower SSIs in skin cancer surgery
There’s a lack of evidence from randomized clinical trials of the role of antibiotic prophylaxis in reducing SSI rates among patients undergoing...
Feature
Widespread carboplatin, cisplatin shortages: NCCN survey
Only 64% of centers said they are still able to continue treating all current patients receiving carboplatin.